- AI drew over $18B in 2025, about 46% of the $46.8B healthcare venture total, even as overall funding fell 12% YoY.
- Capital shifted toward healthtech (+5.3%) and devices (+1.5%) while biopharma (-19%) and diagnostics/tools (-33%) declined.
- AI funding concentrated in mega-rounds, with deals over $300M making up 40% of healthcare AI spend in 2025.
- Deal volume slipped ~7% and healthcare-focused VC fundraising dropped to $7B, far below the $41B peak in 2021.
Read More
The 2026 Healthcare Investments and Exits report from Silicon Valley Bank presents a healthcare venture landscape in flux, where AI is not just a growing niche but has become central—securing nearly half of all investment dollars in 2025. This marks a profound rebalancing in capital allocation, with AI-oriented companies capturing ~46% of the sector’s total $46.8 billion, even as total investment declined 12% compared to the previous year.
Sectoral bifurcations are stark. While healthtech and device sectors modestly expanded, biopharma and diagnostics/tools have seen double-digit declines. The drop in biopharma (−19%) and diagnostics/tools (−33%) suggests that investors are pulling back from areas with longer development timelines, higher regulatory risk, or less predictable near-term returns.
Another notable trend: big bets are dominating the AI healthcare space. Mega-deals over $300 million accounted for 40% of healthcare AI investment in 2025—this underscores a preference for investing in established AI companies or solutions perceived to have high scalability and impact, rather than spreading capital across numerous smaller, riskier ventures.
Fundraising and deal flow have weakened. A 7% drop in deal count and just $7 billion raised by healthcare-focused VCs shows a more constrained liquidity environment. These numbers are hampered by comparisons to 2021’s peak $41 billion haul for funds dedicated to healthcare. The consequence is that only firms with proven product-market fit, efficiency, revenue traction, or clinical validation are likely to succeed.
Strategically, this environment favors startups that are AI-native, operating capital efficiently, and targeting backend or administrative applications (e.g., provider operations) rather than pure clinical or diagnostic innovation. Large VCs may consolidate power, given their ability to fund mega-rounds. Entities without demonstrable revenue or near-term scalability will likely struggle to attract capital, particularly in biopharma and diagnostics.
However, risks loom. The concentration of capital into mega-deals raises valuation and exit risk. Declines in biopharma and clinical diagnostics may reduce pipeline diversity. Fundraising constraints may slow innovation, especially for early-stage firms. Regulatory, ethical, and clinical validation challenges remain critical uncertainty vectors.
Open questions:
- Which AI subsectors will sustain growth post-mega rounds, particularly those with clinical impact versus administrative utility?
- How will reimbursement, regulatory approval, and liability frameworks evolve to accommodate AI-driven clinical tools?
- Can biopharma and diagnostics rebound, or is this a structural shift?
- What will be the exit strategy landscape for AI healthcare firms, especially if public markets remain cautious?
Supporting Notes
- Total healthcare venture investment in 2025 was $46.8 billion, down 12% YoY, with AI investments exceeding $18 billion representing ~46% of the total.
- Healthtech investment grew by 5.3%, device investment by 1.5%; biopharma investment declined 19%, diagnostics/tools dropped 33%.
- Deal counts across healthcare fell 7%, and only $7 billion was raised by healthcare-focused VC funds in 2025—substantially below the 2021 peak of $41 billion.
- More healthcare AI deals over $300 million than in any prior year, with deals above that threshold accounting for 40% of total healthcare AI spending; in previous years, such mega-deals represented around 29-31%.
- Provider operations within healthtech (scheduling, documentation, billing) saw $5.5 billion invested through part of 2025, with projections pointing to a full-year total of $8.25 billion, potentially breaking prior records (~$7.8 billion in 2021); ~52% of provider operations deals involved AI.